Mikkel Christensen

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes
    Mikkel Christensen
    Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Diabetes 64:72-8. 2015
  2. ncbi request reprint The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Center for Diabetes Research, Department of Medicine, Niels Andersen Vej 65, DK 2900 Hellerup, Denmark 45 3997 3320 45 3977 7661
    Expert Opin Drug Discov 9:1223-51. 2014
  3. ncbi request reprint Lixisenatide for the treatment of type 2 diabetes
    A B Petersen
    Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
    Drugs Today (Barc) 49:537-53. 2013
  4. ncbi request reprint Medication review in hospitalised patients to reduce morbidity and mortality
    Mikkel Christensen
    Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Cochrane Database Syst Rev 2:CD008986. 2013
  5. ncbi request reprint GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria J Jespersen
    University of Copenhagen, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 9:17-29. 2013
  6. ncbi request reprint Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Regul Pept 163:96-101. 2010
  7. ncbi request reprint [Colonic malacoplakia treated with sulfamethizole and trimethoprim]
    Mikkel Christensen
    Medicinsk afdeling, Amager Hospital, Denmark
    Ugeskr Laeger 173:509-10. 2011
  8. ncbi request reprint Lixisenatide for type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Hellerup, Denmark
    Expert Opin Investig Drugs 20:549-57. 2011
  9. pmc Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Copenhagen, Denmark
    Diabetes 60:3103-9. 2011
  10. pmc Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes
    Mikkel Christensen
    Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Diabetes 64:72-8. 2015
    ..Our results suggest that during hypoglycemia in patients with T1DM, exogenous GIP increases glucagon responses during the recovery phase after hypoglycemia and reduces the need for glucose administration. ..
  2. ncbi request reprint The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Center for Diabetes Research, Department of Medicine, Niels Andersen Vej 65, DK 2900 Hellerup, Denmark 45 3997 3320 45 3977 7661
    Expert Opin Drug Discov 9:1223-51. 2014
    ..GLP-1RAs are associated with body weight benefits and low rates of hypoglycemia which are welcome in patients with T2DM...
  3. ncbi request reprint Lixisenatide for the treatment of type 2 diabetes
    A B Petersen
    Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
    Drugs Today (Barc) 49:537-53. 2013
    ..Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia. ..
  4. ncbi request reprint Medication review in hospitalised patients to reduce morbidity and mortality
    Mikkel Christensen
    Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Cochrane Database Syst Rev 2:CD008986. 2013
    ..Medication review performed in adult hospitalised patients may lead to better patient outcomes...
  5. ncbi request reprint GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria J Jespersen
    University of Copenhagen, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 9:17-29. 2013
    ..Within recent years, glucagon-like peptide 1 receptor agonists (GLP-1-RA) have emerged as a new treatment option for type 2 diabetes. The GLP-1-RA are administered subcutaneously and differ substantially in pharmacokinetic profiles...
  6. ncbi request reprint Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Regul Pept 163:96-101. 2010
    ..In conclusion, GLP-2, but not GIP, was found to stimulate the release of glucagon in patients with T1DM, suggesting a role for GLP-2 in the postprandial hyperglucagonaemia characterising individuals with T1DM...
  7. ncbi request reprint [Colonic malacoplakia treated with sulfamethizole and trimethoprim]
    Mikkel Christensen
    Medicinsk afdeling, Amager Hospital, Denmark
    Ugeskr Laeger 173:509-10. 2011
    ..The condition resolved during three months of antibiotic treatment with sulfamethizole and trimethoprim...
  8. ncbi request reprint Lixisenatide for type 2 diabetes mellitus
    Mikkel Christensen
    University of Copenhagen, Gentofte Hospital, Diabetes Research Division, Department of Internal Medicine F, Hellerup, Denmark
    Expert Opin Investig Drugs 20:549-57. 2011
    ..Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM...
  9. pmc Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Copenhagen, Denmark
    Diabetes 60:3103-9. 2011
    ..To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) effects on insulin and glucagon release in 10 healthy male subjects ([means ± SEM] aged 23 ± 1 years, BMI 23 ± 1 kg/m(2), and HbA(1c) 5.5 ± 0.1%)...
  10. pmc Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
    ..To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with or without type 2 diabetes mellitus...
  11. ncbi request reprint Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
    Mikkel Christensen
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Curr Diab Rep 10:124-32. 2010
    ....
  12. pmc The alpha-cell as target for type 2 diabetes therapy
    Mikkel Christensen
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:369-81. 2011
    ..At present, available pharmacological agents based on the glucose-dependent glucagonostatic effects of GLP-1 represent the most favorable way to apply constraints to the alpha-cell in type 2 diabetes...
  13. ncbi request reprint Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes
    Espen Jimenez-Solem
    University of Copenhagen, Gentofte Hospital, Department of Internal Medicine F, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Curr Opin Mol Ther 12:790-7. 2010
    ..If dulaglutide possesses similar efficacy to other GLP-1 analogs, the once-weekly treatment will most likely be welcomed by patients with T2DM...
  14. ncbi request reprint Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans
    Anne Nissen
    Novo Nordisk Foundation Center for Basic Metabolic Research A N, F K K, J J H, B H, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark and Center for Diabetes Research M C, F K K, T V, Department of Medicine, Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark
    J Clin Endocrinol Metab 99:E2325-9. 2014
    ..Its role in human bone homeostasis, however, is unknown...
  15. ncbi request reprint Glucagon and type 2 diabetes: the return of the alpha cell
    Asger Lund
    Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Curr Diab Rep 14:555. 2014
    ..Furthermore, potential advantages and limitations of suppressing glucagon secretion or antagonizing the glucagon receptor, respectively, in the treatment of patients with type 2 diabetes will be discussed. ..
  16. pmc Therapy for obesity based on gastrointestinal hormones
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Rev Diabet Stud 8:339-47. 2011
    ..This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity...
  17. ncbi request reprint Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
    Mikkel Christensen
    Amager Hospital, Department of Internal Medicine, University of Copenhagen, Denmark
    IDrugs 12:503-13. 2009
    ....
  18. ncbi request reprint Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease
    Thomas Idorn
    Department of Nephrology T I, M B J, M H, B F R, Rigshospitalet, University of Copenhagen, DK 2100 Copenhagen, Denmark Diabetes Research Division, Department of Internal Medicine F K K, M C, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark and The NNF Center for Basic Metabolic Research, Department of Biomedical Sciences F K K, J J H, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Clin Endocrinol Metab 99:2457-66. 2014
    ..The affect of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear...